Last update Oct. 15, 2016


Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Second-generation cephalosporin for injection or parenteral administration.

Like most cephalosporins for which data are available, excretion occurs in breast milk in very small amount and it is clinically insignificant (Cho 1982, Novelli 1983, Matsuda 1984).

Cephalosporins are widely used in the Pediatric practice with a good tolerance, even in the neonatal period, so it is very unlikely that in small amounts through milk would be a cause of problems in the infant.

Be aware of the possibility of false negative results of cultures in febrile infants whose mothers are taking antibiotics as well as the possibility of gastroenteritis (Ito 1993) by altering the intestinal flora.


We do not have alternatives for Cefotetan since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Cefotetan in other languages or writings:


Cefotetan belongs to this group or family:


Main tradenames from several countries containing Cefotetan in its composition:


Variable Value Unit
Oral Bioavail. Baja - Poor %
Molecular weight 576 daltons
Protein Binding 76 - 91 %
VD 0.15 l/Kg
Tmax 1.5 - 3 hours
3 - 4.6 hours
Theoretical Dose 0.04 - 0.08 mg/Kg/d
Relative Dose 0.3 - 0.6 %
Ped.Relat.Dose 0.1 - 0.25 %


  1. Martin C, Thomachot L, Albanese J. Clinical pharmacokinetics of cefotetan. Clin Pharmacokinet. 1994 Abstract
  2. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  3. Fulton B, Moore LL. Antiinfectives in breastmilk. Part I: Penicillins and cephalosporins. J Hum Lact. 1992 Abstract
  4. Matsuda S. Transfer of antibiotics into maternal milk. Biol Res Pregnancy Perinatol. 1984;5(2):57-60. Abstract
  5. Novelli A, Mazzei T, Ciuffi M et al. The penetration of intramuscular cefotetan disodium into human extra-vascular fluid and maternal milk secretion. Chemotherapy (Basel). 1983;2:337-42. 1983
  6. Cho N, Fukunaga K, Kuni K. Fundamental and clinical studies on cefotetan (YM09330) in the field of obstetrics and gynecology. Chemotherapy (Tokyo). 1982;30 (suppl 1):832-42. 1982

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM